Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-04-21
Tempus AI, Inc.
Tempus provides genomic diagnostics, clinical workflow software, and multimodal data analytics to physicians, health systems, and life sciences companies.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Control Could Outgrow Lab Economics
The company looks strongest as a regulated data-and-workflow stack, not just a genomics lab. If it turns diagnostics-fed data rights into recurring evidence and operating-layer revenue while sustaining margin progress, a 2-5x outcome over five years is plausible.

Analysis

Thesis
Tempus can compound from a fast-growing diagnostics company into a higher-value oncology operating layer if its governed data rights and Hub/Lens workflow surfaces keep pulling more tests, evidence work, and biopharma spend into recurring contracts faster than regulation or dilution slows it.
Last Economy Alignment
Cheaper cognition makes Tempus’ owned data, clinical verification, and workflow placement more valuable; it is not a thin seat-based wrapper. The main brake is regulated-data permissioning and the need to prove that data/apps can lift cash generation, not just product breadth.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The upside case is driven by four things happening together: continued oncology and hereditary test growth, MRD scaling, Data & Applications becoming a larger share of revenue, and Tempus wrapping workflow and evidence products into bigger enterprise contracts. I do not assume a software-style rerating. I assume some multiple compression from today, so most of the value creation comes from revenue scale and a more self-funding mix.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Tempus can ship AI features; it is whether it can convert scientific credibility, data rights, and workflow presence into repeatable, higher-margin contracts fast enough to self-fund growth. If data monetization stays lumpy, reimbursement slows, or regulation tightens around clinical data use, the business can keep growing while the stock is valued more like a diagnostics company than a healthcare operating layer.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.68
They control a hard-to-copy pool of cancer data plus the doctor workflow where tests get ordered and updated, so cheaper AI makes their dataset and software more useful instead of replacing them. The risk is that privacy rules, clinical liability, or bigger healthcare platforms limit how much of that value they can keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$72.83
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case